Figure 8.

Increased expression of MYCL and CD8⁺ T cell priming capacity by activated CD141⁺ dendritic cells (DC). (A) Gene expression of MYCL 2 h after activation of DC subsets in vivo. (B) Priming of autologous naïve MART-1-specific CD8⁺ T cells by CD141⁺ DC and CD1c⁺ DC, shown as the percentage of CD8⁺ T cells staining for MART-1-specific pentamer. (C) Effector function of MART-1-specific CD8⁺ T cells primed by CD141⁺ DC and CD1c⁺ DC expressed as % of antigen (Ag)-specific cells producing effector molecules CD107a, TNF, IFNγ, or IL-2 (left) and % of Ag-specific CD8⁺ T cells simultaneously producing one or more effector molecules (right).